Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat

Authors: V Nedelcheva Kristensen, T Kristensen, A-L Børresen-Dale

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Glutathione S transferases are dimeric molecules, catalysing the conjugation of activated (acetylated, alkylated, hydroxylated, oxygenated) molecules of xenobiotics to glutathione. Large deletions in the genes coding for some of the enzymes (GSTM1, GSTT1) are known and related to deficiency in conjugation of the metabolites of xenobiotics. Alterations in glutathione metabolism have been shown to have an important impact on the cytotoxicity of various free radical-producing anticancer drugs, like adriamycin. The overexpression of GSTP1 was shown to be involved in the acquisition of resistance to anticancer drugs like adriamycin, cisplatin, melphalan and etoposide. Two polymorphisms in GSTP1 are known: a point mutation in exon 5 with a possible functional role, leading to changes in the kinetic properties of the enzyme, and a repeat of AAAAT in the 5' untranslated region immediately upstream of an extensively methylated CpG island. Poly AT-rich repeats are implicated as differential enhancers of transcriptional activation. Here we report that the repeat in the AT-rich area of the 5' untranslated region is further degenerated by insertions of CAC, ATT and other motifs, and describe a detailed analysis of the polymorphism with a putative role in the regulation of transcriptional activation. …
Metadata
Title
Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat
Authors
V Nedelcheva Kristensen
T Kristensen
A-L Børresen-Dale
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr177

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine